Amgen Inc. stock price, AMGN

Amgen Inc. stock chart:



Amgen Inc. close price: 160.22

Stock price forecast:

UP TO +0.46%
Target: 160.96

Total forecasts: 90
Reached: 8 (8.89%)

Total Win: 9.40 (5.74%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
909199.89%11.450.08%13,162.43-24.39-0.19%-12.94-0.09%
303100.00%0.000.00%4,966.820.000.00%0.000.00%
141500.00%0.000.00%2,403.300.000.00%0.000.00%
7800.00%0.000.00%1,281.760.000.00%0.000.00%

Showing 1-10 of 623 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-07-24160.22160.970000-00-00
2017-07-23160.22160.910000-00-00
2017-07-22160.22161.10000-00-00
2017-07-21160.22161.10000-00-00
2017-07-20160.22160.830000-00-00
2017-07-19160.22161.080000-00-00
2017-07-18160.221610000-00-00
2017-07-17160.22160.80000-00-00
2017-07-16160.22160.950000-00-00
2017-07-15160.22160.950000-00-00

Amgen Inc. latest news:


  • 07/20/2017 14:34:26

    BRIEF-Amgen says FDA accepts biologics license application for Aimovig

    * FDA accepts biologics license application for Aimovig™ (erenumab)

  • 07/17/2017 10:49:14

    Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA

    Amgen Inc AMGN and partner UCB SA UCBJF announced that the FDA has issued a complete response letter CRL for the biologics license application BLA for Evenity romosozumab Amgen is looking to get Evenity approved for the treatment of postmenopausal women with osteoporosis The

  • 07/12/2017 14:18:09

    BRIEF-Amgen says second phase 3 study shows kyprolis regimen significantly improves overall survival in patients with ...

    Amgen Inc(AMGN). * Second phase 3 study shows Kyprolis regimen significantly improves overall survival in patients with relapsed multiple myeloma. * Amgen Inc(AMGN) - adverse events observed in updated analysis were consistent with those previously reported for Aspire. * Amgen Inc (AMGN) - study met key secondary endpoint.

  • 07/12/2017 14:17:57

    BRIEF-Amgen says second phase 3 study shows kyprolis regimen significantly improves overall survival in patients with relapsed multiple myeloma

    * Second phase 3 study shows Kyprolis (carfilzomib) regimen significantly improves overall survival in patients with relapsed multiple myeloma

  • 06/12/2017 10:02:52

    Coherus BioSciences stock drops 27% after FDA fails to approve drug

    Coherus BioSciences Inc. shares dropped 27.2% to $15.03 in midday trade Monday after the company said that the Food and Drug Administration failed to approve its drug. The drug, CHS-1701, is a biosimilar version of Amgen Inc.'s Neulasta , which helps prevent infections for patients receiving chemotherapy. The FDA asked for a sample reanalysis and "certain additional manufacturing related process information," but did not ask the company to do a clinical study, Coherus said. The company said that the information requests would probably cause a delay to market of about 13 months, but it plans to work with the FDA to get CHS-1701 approved. Biosimilar drugs are expected to bring down drug prices and save the U.S. health care system billions of dollars, but few biosimilars have been approved since the FDA created a pathway for approval seven years ago. Coherus shares have dropped 36.1% over the last three months, compared with a 2.2% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 06/06/2017 15:41:59

    Regeneron, Sanofi urge court to reverse ban on cholesterol drug

    A federal appeals court hinted on Tuesday it may let Sanofi AG and Regeneron Pharmaceuticals Inc (REGN) sell a cholesterol drug Amgen Inc (AMGN) has been trying to block on patent infringement grounds, according to lawyers and analysts who attended oral arguments in the case.

  • 05/22/2017 08:28:32

    UPDATE: Amgen Inc. stock drops 2% on drug's cardiovascular risk; no approval expected this year

    Amgen Inc. shares dropped 1.9% in morning trade Monday after the company said that it has observed new cardiovascular risks for its Evenity drug, which is intended to reduce risk of fractures in patients with osteoporosis, and that it does not expect the drug to get approved this year. Shares of its partner on the drug, UCB , declined 17.9%. Amgen said it saw this new cardiovascular safety signal in its late-stage trial for the drug, with Evenity having an imbalance in serious cardiovascular adverse events as compared with the current standard of care in osteoporosis, alendronate. Sean Harper, Amgen's executive vice president of research and development, said that "the newly observed cardiovascular safety signal will have to be assessed as part of the overall benefit:risk profile for Evenity" and that it would work with UCB to evaluate the data with global regulators and medical experts. The latest results are "clearly negative, and very surprising," said EvercoreISI analyst Umer Raffat. The clinical trial met its two primary endpoints and its key secondary endpoint, Amgen also said. Amgen shares have dropped 11.1% over the last three months, and UCB shares have declined 8.2%, compared with a 1.1% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/21/2017 18:56:28

    Higher rate of heart problems seen with Amgen bone drug in trial

    Amgen Inc(AMGN) and UCB SA said on Sunday they did not expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial. The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the Food and Drug Administration.

  • 05/21/2017 18:56:02

    UPDATE 2-Higher rate of heart problems seen with Amgen bone drug in trial

    May 21 (Reuters) - Amgen Inc and UCB SA said on Sunday they did not expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.

  • 04/26/2017 16:31:43

    BRIEF-Amgen reports Q1 GAAP earnings per share $2.79

    * Says 2017 earnings per share guidance increased to $10.64-$11.32 on GAAP basis, and $12.00-$12.60 on non-GAAP basis

  • 04/26/2017 15:09:34

    Cost controls help offset lower Amgen first-quarter drug sales

    (Reuters) - Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

  • 04/26/2017 14:21:19

    Amgen shares slide on weak Enbrel sales

    Shares of Amgen Inc. slid in Wednesday's extended session after the biopharmaceutical company reported a double-digit sales decline of its blockbuster drug. Amgen reported its first-quarter earnings rose to $2.07 billion, or $2.79 a share, from $1.9 billion, or $2.50 a share, a year earlier. On an adjusted basis, the pharmaceutical giant would have earned $3.15 a share. Revenue slipped 1% to $5.46 billion. Analysts surveyed by FactSet had forecast earnings of $2.99 a share on revenue of $5.61 billion. Amgen also said that sales of its rheumatoid arthritis and plaque psoriasis drug Enbrel fell 15% due to increased competition. The drug maker kept its 2017 revenue outlook unchanged at $22.3 billion to $23.1 billion but raised the lower end of its adjusted earnings per share forecast to a range of $12 to $12.60. It had previously projected $11.80 to $12.60. Amgen shares dropped 2.9% after hours. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/26/2017 14:12:48

    Amgen first-quarter profit exceeds Street estimates on lower costs

    (Reuters) - Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

  • More trends:

    Amicus Therapeutics, Inc.FOLD | Amkor Technology, Inc.AMKR | Amphastar Pharmaceuticals, Inc.AMPH | Amsurg Corp.AMSG | Amsurg Corp.AMSGP | Amtech Systems, Inc.ASYS | AmTrust Financial Services, Inc.AFSI+0.23% | Amyris, Inc.AMRS | Anacor Pharmaceuticals, Inc.ANAC | ANADIGICS, Inc.ANAD |